Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas.
Lu X, Vano Y, Helleux A, Su X, Lindner V, Davidson G, Mouawad R, Spano JP, Rouprêt M, Elaidi R, Compérat E, Verkarre V, Sun C, Chevreau C, Bennamoun M, Lang H, Tricard T, Cheng W, Xu L, Davidson I, Yan F, Fridman WH, Sautes-Fridman C, Oudard S, Malouf GG. Lu X, et al. Among authors: elaidi r. Clin Cancer Res. 2023 Apr 3;29(7):1279-1291. doi: 10.1158/1078-0432.CCR-22-2133. Clin Cancer Res. 2023. PMID: 36374555
Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
Beuselinck B, Job S, Becht E, Karadimou A, Verkarre V, Couchy G, Giraldo N, Rioux-Leclercq N, Molinié V, Sibony M, Elaidi R, Teghom C, Patard JJ, Méjean A, Fridman WH, Sautès-Fridman C, de Reyniès A, Oudard S, Zucman-Rossi J. Beuselinck B, et al. Among authors: elaidi r. Clin Cancer Res. 2015 Mar 15;21(6):1329-39. doi: 10.1158/1078-0432.CCR-14-1128. Epub 2015 Jan 12. Clin Cancer Res. 2015. PMID: 25583177 Free article.
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Vano YA, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, Maillet D, Gross-Goupil M, Tournigand C, Laguerre B, Barthélémy P, Coquan E, Gravis G, Houede N, Cancel M, Huillard O, Beuzeboc P, Fournier L, Méjean A, Cathelineau X, Doumerc N, Paparel P, Bernhard JC, de la Taille A, Bensalah K, Tricard T, Waeckel T, Pignot G, Braychenko E, Caruso S, Sun CM, Verkarre V, Lacroix G, Moreira M, Meylan M, Bougouïn A, Phan L, Thibault-Carpentier C, Zucman-Rossi J, Fridman WH, Sautès-Fridman C, Oudard S. Vano YA, et al. Among authors: elaidi r. Lancet Oncol. 2022 May;23(5):612-624. doi: 10.1016/S1470-2045(22)00128-0. Epub 2022 Apr 4. Lancet Oncol. 2022. PMID: 35390339 Clinical Trial.
Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma.
Auclin E, Bourillon C, De Maio E, By MA, Seddik S, Fournier L, Auvray M, Dautruche A, Vano YA, Thibault C, Joly F, Brunereau L, Gomez-Roca C, Chevreau C, Elaidi R, Oudard S. Auclin E, et al. Among authors: elaidi r. Clin Genitourin Cancer. 2017 Jun;15(3):350-355. doi: 10.1016/j.clgc.2017.01.022. Epub 2017 Feb 1. Clin Genitourin Cancer. 2017. PMID: 28216276
Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer.
Meylan M, Petitprez F, Becht E, Bougoüin A, Pupier G, Calvez A, Giglioli I, Verkarre V, Lacroix G, Verneau J, Sun CM, Laurent-Puig P, Vano YA, Elaïdi R, Méjean A, Sanchez-Salas R, Barret E, Cathelineau X, Oudard S, Reynaud CA, de Reyniès A, Sautès-Fridman C, Fridman WH. Meylan M, et al. Among authors: elaidi r. Immunity. 2022 Mar 8;55(3):527-541.e5. doi: 10.1016/j.immuni.2022.02.001. Epub 2022 Feb 28. Immunity. 2022. PMID: 35231421 Free article.
49 results